| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net loss | ||||||
-49,451 | 31,851 | -113,483 | -48,719 | -43,633 | -9,670 | -5,387 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Change in fair value of warrant liability | ||||||
-11,386 | -16,337 | 30,218 | -638 | - | - | - |
Impairment of intangible asset | ||||||
- | - | 20,723 | 15,828 | - | - | - |
Stock-based compensation | ||||||
8,597 | 7,807 | 5,167 | 4,606 | 3,940 | 251 | 748 |
Amortization of intangible asset | ||||||
5,022 | 7,187 | 5,022 | - | - | - | - |
Accretion of discounts on marketable securities | ||||||
385 | - | - | - | - | - | - |
Interest and related guarantee fees paid in kind | ||||||
- | - | 896 | - | - | - | - |
Amortization of debt discounts and debt issuance costs | ||||||
- | 1,484 | 482 | - | - | - | - |
Loss on extinguishment of debt | ||||||
- | -21,549 | -3,545 | - | - | - | - |
Gain on sale of subsidiary | ||||||
- | 130,832 | - | - | - | - | - |
Deferred income tax expense | ||||||
- | - | 1,958 | -2,884 | - | - | - |
Deferred income tax expense (benefit) | ||||||
- | - | - | - | -450 | -480 | -93 |
Depreciation | ||||||
77 | 46 | 10 | 10 | 11 | 9 | 3 |
Impairment/loss on investment in Antisense Therapeutics | ||||||
- | - | - | 550 | 551 | - | - |
Change in fair value of foreign currency forward contracts | ||||||
- | - | - | - | 438 | -279 | -159 |
Changes in operating assets and liabilities: | ||||||
Accounts receivable | ||||||
663 | 42 | 1,584 | - | - | - | - |
Inventory | ||||||
-1,618 | 3,437 | 511 | - | - | - | - |
Prepaid expenses and other current assets | ||||||
-3,079 | 3,028 | 444 | -848 | 1,165 | 309 | -100 |
Accrued liabilities | ||||||
- | - | - | - | - | - | 994 |
Other assets | ||||||
798 | -381 | 536 | 88 | 52 | -2 | - |
Accounts payable | ||||||
2,153 | -63 | 158 | -1,702 | 1,737 | 236 | 519 |
Accrued and other liabilities | ||||||
-2,647 | -1,142 | 3,043 | 475 | 1,263 | 736 | - |
Net cash used in operating activities | ||||||
-44,784 | -84,576 | -45,336 | -31,714 | -37,360 | -9,504 | -3,475 |
Cash flows from investing activities: | ||||||
Payment for acquisitions | ||||||
- | 24,655 | 7,500 | 3,392 | 3,168 | - | - |
Purchases of property and equipment | ||||||
74 | 326 | - | - | - | - | - |
Purchases of marketable securities | ||||||
56,187 | - | - | - | - | - | - |
Sales and maturities of marketable securities | ||||||
35,500 | - | - | - | - | - | - |
Proceeds from sale of subsidiary | ||||||
- | 159,311 | - | - | - | - | - |
Investment in Antisense Therapeutics | ||||||
- | - | - | - | 1,101 | - | - |
Purchase of equipment | ||||||
- | - | - | - | 25 | 24 | 2 |
Net cash provided by (used in) investing activities | ||||||
-20,761 | 134,330 | -7,500 | -3,392 | -4,294 | -24 | -2 |
Cash flows from financing activities: | ||||||
Proceeds from long-term debt, net | ||||||
- | 44,930 | 39,987 | 19,316 | - | - | - |
Payment for loss on extinguishment of debt | ||||||
- | 9,990 | 1,300 | - | - | - | - |
Repayment of long-term debt | ||||||
- | 85,000 | 22,261 | - | - | - | - |
Proceeds from issuance of ordinary shares, net | ||||||
- | 33,508 | 26,384 | 32,298 | - | - | 14,924 |
Proceeds from share subscription to Novo | ||||||
- | 22,383 | - | - | - | - | - |
Proceeds from issuance of ordinary shares in connection with at-the-market offering | ||||||
- | 8,596 | 73 | - | - | - | - |
Proceeds from exercise of warrants | ||||||
- | 1,176 | - | - | - | - | - |
Proceeds from initial public offering, net | ||||||
- | - | - | - | 19,475 | - | - |
Proceeds from issuance of ordinary shares and warrants, net | ||||||
- | - | - | - | 58,341 | 10,193 | - |
Proceeds from exercise of stock options | ||||||
179 | 96 | 626 | 120 | - | - | - |
Payments related to tax withholding for net-share settled equity awards | ||||||
92 | 473 | - | - | - | - | - |
Acquisition of non-controlling interest | ||||||
- | - | - | 1,414 | 412 | - | - |
Net cash (used in) provided by financing activities | ||||||
87 | 15,226 | 43,509 | 50,320 | 77,404 | 10,193 | 14,924 |
Net decrease in cash and cash equivalents | ||||||
-65,458 | 64,980 | -9,327 | 15,214 | - | - | - |
Effect of exchange rate changes on cash and cash equivalents | ||||||
- | - | - | - | 241 | 70 | -455 |
Net increase (decrease) in cash and cash equivalents | ||||||
- | - | - | - | 35,991 | 735 | 10,992 |
Supplemental disclosures of cash flow information: Cash paid during the year for: | ||||||
Interest | ||||||
- | 11,122 | 2,935 | 20 | - | - | - |
Income taxes other, net of refunds | ||||||
419 | 1 | 127 | - | - | - | - |
Supplemental non-cash financing activities: | ||||||
Issuance of shares to settle debt | ||||||
- | 2,805 | - | - | - | - | - |
Changes in unrealized gain on marketable securities | ||||||
3 | - | - | - | - | - | - |
Ordinary shares issued for acquisition of COR-005 | ||||||
- | - | - | - | 33,211 | - | - |
Ordinary shares exchanged for BioPancreate | ||||||
- | - | - | - | - | 43 | 2,915 |